2026-07-06T11:34:36Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/721542025-02-13T16:49:43Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Martínez Cuadrón, David author Serrano, Josefina author Mariz, José author Gil, Cristina author Tormo, Mar author Martínez Sánchez, María Del Pilar author Rodríguez Arbolí, Eduardo author García Boyero, Raimundo author Rodríguez Medina, Carlos author Martínez Chamorro, Carmen author Polo, Marta author Bergua, Juan author Aguiar, Eliana author Amigo, María author Herrera, Pilar author Alonso Domínguez, Juan Manuel author Bernal, Teresa author Espadana, Ana author Sayas, María author Algarra, Lorenzo author Vidriales, María B. author Vasconcelos, Graça author Vives, Susana author Pérez Encinas, Manuel author López, Aurelio author Noriega Concepción, Víctor author García Fortes, María author Chillón, María author Rodríguez Gutiérrez, Juan author Calasanz, María author Labrador, Jorge author López, Juan author Boluda, Blanca author Rodríguez Veiga, Rebeca author Martínez López, Joaquín author Barragán, Eva author Sanz, Miguel author Montesinos, Pau author 2022 This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant. 2072-6694 10.3390/cancers14112817 https://hdl.handle.net/20.500.14352/72154 https://doi.org/10.3390/cancers14112817 https://www.mdpi.com/2072-6694/14/11/2817 Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia